Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.

Auteurs

Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Kalinsky K, Cortés J, Shaughnessy JO, Diéras V, Carey LA, Gianni L, Piccart-Gebhart M, Loibl S, Yoon OK, Pan Y, Hofsess S, Phan SC, Hurvitz SA

  • Date de publication

    Février 2024

  • Type

    Article

  • Revue

    J Clin Oncol

  • Nom du chercheur

    PICCART MARTINE

  • Hôpital

    Institut Jules Bordet

  • Service

    Médecine Oncologique

  • PMID

    38422473

  • DOI

    10.1200/JCO.23.01409